KYTX
Price:
$2.27
Market Cap:
$98.11M
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory...[Read more]
Industry
Biotechnology
IPO Date
2024-02-09
Stock Exchange
NASDAQ
Ticker
KYTX
According to Kyverna Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.70. This represents a change of -53.32% compared to the average of -1.50 of the last 4 quarters.
The mean historical PE Ratio of Kyverna Therapeutics, Inc. over the last ten years is -98.02. The current -0.70 PE Ratio has changed -28.58% with respect to the historical average. Over the past ten years (40 quarters), KYTX's PE Ratio was at its highest in in the March 2025 quarter at -0.47. The PE Ratio was at its lowest in in the December 2022 quarter at -38.06.
Average
-98.02
Median
-28.09
Minimum
-334.77
Maximum
-1.12
Discovering the peaks and valleys of Kyverna Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.15%
Maximum Annual PE Ratio = -1.12
Minimum Annual Increase = -99.66%
Minimum Annual PE Ratio = -334.77
Year | PE Ratio | Change |
---|---|---|
2024 | -1.12 | -99.66% |
2023 | -334.77 | 1.15% |
2022 | -26.79 | -8.80% |
The current PE Ratio of Kyverna Therapeutics, Inc. (KYTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-120.90
5-year avg
-98.02
10-year avg
-98.02
Kyverna Therapeutics, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kyverna Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kyverna Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Kyverna Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Kyverna Therapeutics, Inc. (KYTX)?
What is the highest PE Ratio for Kyverna Therapeutics, Inc. (KYTX)?
What is the 3-year average PE Ratio for Kyverna Therapeutics, Inc. (KYTX)?
What is the 5-year average PE Ratio for Kyverna Therapeutics, Inc. (KYTX)?
How does the current PE Ratio for Kyverna Therapeutics, Inc. (KYTX) compare to its historical average?